HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

JNK Mitogen-Activated Protein Kinases

Subscribe to New Research on JNK Mitogen-Activated Protein Kinases

A subgroup of mitogen-activated protein kinases that activate TRANSCRIPTION FACTOR AP-1 via the phosphorylation of C-JUN PROTEINS. They are components of intracellular signaling pathways that regulate CELL PROLIFERATION; APOPTOSIS; and CELL DIFFERENTIATION.

Also Known As:

c-jun Amino-Terminal Kinase; c-jun N-Terminal Kinase; jun-NH2-Terminal Kinase; jun-NH2-Terminal Kinases; Amino-Terminal Kinase, c-jun; JNK Mitogen Activated Protein Kinases; N-Terminal Kinase, c-jun; c jun Amino Terminal Kinase; c jun N Terminal Kinase; jun NH2 Terminal Kinase; jun NH2 Terminal Kinases

Networked: 1056 relevant articles (15 outcomes, 94 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bonny, Christophe: 14 articles (01/2012 - 09/2003)
2.	Zhang, Guang-Yi: 11 articles (04/2012 - 02/2005)
3.	Firestein, Gary S: 7 articles (06/2015 - 03/2002)
4.	Pei, Dong-Sheng: 7 articles (01/2012 - 02/2005)
5.	Hirt, Lorenz: 7 articles (01/2012 - 09/2003)
6.	Yoshimura, Koichi: 6 articles (01/2015 - 12/2005)
7.	Chen, Jun: 6 articles (01/2012 - 06/2005)
8.	Ji, Ru-Rong: 6 articles (11/2010 - 03/2006)
9.	Borsello, Tiziana: 6 articles (11/2009 - 09/2003)
10.	Kaneto, Hideaki: 6 articles (02/2008 - 10/2004)

Related Diseases

1.	Insulin Resistance 09/01/2015 - "Leukocyte cell-derived chemotaxin 2 (LECT2) is a recently discovered novel hepatokine, leading to skeletal muscle insulin resistance by activating c-Jun N-terminal kinase (JNK). " 07/01/2015 - "Moreover, cocoa-rich diet suppressed c-Jun N-terminal kinase and p38 activation caused by insulin resistance. " 10/01/2013 - "A relatively recent investigation finds the role of c-Jun-N-terminal kinase (JNK3) in AD which also seems to bear a link with insulin resistance. " 09/01/2013 - "The stress-activated c-Jun N-terminal kinase (JNK) has been increasingly recognized as a central mediator of insulin resistance. " 04/05/2013 - "HHcy activated c-Jun N-terminal kinase (JNK), the downstream signal of ER stress in adipose tissue, and activated JNK participated in insulin resistance by inhibiting Akt activation. "
2.	Brain Injuries (Brain Injury) 12/01/2013 - "Previous studies have strongly suggested that c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. " 05/12/2006 - "Our previous studies and the others have strongly suggested that c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. " 01/30/2006 - "Our previous studies and those of others have strongly suggested that c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. " 02/01/2012 - "[Effect of expression of c-jun N-terminal kinase on neuron autophagy following diffuse brain injury in rats]." 08/01/2011 - "It is demonstrated that the c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. "
3.	Ischemia 01/01/2014 - "c-Jun N-terminal kinase (JNK), a stress-activated MAPK, is activated during cardiac ischemia-reperfusion (IR). " 10/01/2009 - "Using a simulated ischemia-reperfusion (I/Re) model with primary cultured rat neonatal cardiomyocytes, I/Re induced a rapid, time-dependent phosphorylation of c-Jun N-terminal kinase (JNK), with significant elevation at 0.25 h and a peak at 0.5h during reperfusion. " 12/01/2008 - "To investigate the effect and mechanism of JNK mitogen-activated protein kinases (JNK MAPKs) inhibitor SP 600125 on hemodynamics after ischemia/reperfusion (I/R) injury to heart in anesthetized rats. " 06/01/2008 - "Whether the response of the fetal heart to ischemia-reperfusion is associated with activation of the c-Jun N-terminal kinase (JNK) pathway is not known. " 11/30/2007 - "The d-retro-inverso form of c-Jun N-terminal kinase-inhibitor (D-JNKI1), a cell-permeable inhibitor of JNK, powerfully reduces neuronal death induced by permanent and transient ischemia, even when administered 6 h after the ischemic insult, offering a clinically relevant window. "
4.	Reperfusion Injury 05/01/2012 - "To investigate the protective effects and mechanism of SP600125-specificity inhibitor of c-Jun N-terminal kinase (JNK)on lung ischemia /reperfusion injury in rats. " 05/08/2007 - "Accumulating evidence suggests that c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in renal ischemia/reperfusion injury. " 05/15/2006 - "In small intestinal ischemia reperfusion injury, we investigated the pathophysiological role of c-Jun NH2 terminal kinase (JNK) and p38 in order to determine whether the dual inhibition of JNK and p38 was beneficial. " 05/15/2006 - "JNK (c-Jun NH2 terminal kinase) and p38 during ischemia reperfusion injury in the small intestine." 08/01/2003 - "Apoptotic cell death and c-Jun N-terminal kinase (JNK) activation occur after hepatic ischemia/reperfusion injury. "
5.	Pancreatitis 04/01/2012 - "The objective of this study was to investigate the effects of the c-Jun N-terminal kinase (JNK) signaling pathway on rats' acute pancreatitis-associated lung injury (APALI). " 04/01/2012 - "Effects of c-Jun N-terminal kinase signaling pathway on severe acute pancreatitis-associated lung injury." 07/25/2008 - "In vitro studies using freshly prepared pancreatic acini show that genetic deletion of PAR2 reduces bile salt-induced pathological calcium transients, acinar cell injury, and activation of c-Jun N-terminal kinase, whereas genetic deletion of PAR2 has the opposite or no effect on these pancreatitis-related events when they are elicited, in vitro, by caerulein stimulation. " 05/01/2015 - "Additionally, GS treatment suppressed the activation of extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) in the pancreas in cerulein-induced pancreatitis. " 09/24/2000 - "Mitogen-activated protein kinase (MAPK) family members such as c-jun N-terminal kinase (JNK) may act as signal transducers early during pancreatitis development and evidence indicates that MAPK phosphatases (MKP) downregulate MAPK. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Glucose (Dextrose)
3.	Protein Kinases (Protein Kinase)
4.	anthra(1,9-cd)pyrazol-6(2H)-one
5.	Reactive Oxygen Species (Oxygen Radicals)
6.	Insulin (Novolin)
7.	Mitogen-Activated Protein Kinase 3
8.	Caerulein (Ceruletide)
9.	Messenger RNA (mRNA)
10.	Serine (L-Serine)

Related Therapies and Procedures

1.	Ligation
2.	Resuscitation
3.	Drug Therapy (Chemotherapy)
4.	Lasers (Laser)
5.	Intraperitoneal Injections